WealthTrust Axiom’s Clovis Oncology, Inc. CLVS Stock Holding History

WealthTrust Axiom’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-60,000	Closed	-$71K	–	260
2022 Q3	$71K	Buy	60,000 +5,000	+9%	+$7.79K	0.03%	225
2022 Q2	$99K	Buy	55,000 +23,000	+72%	+$33.9K	0.04%	225
2022 Q1	$64K	Buy	32,000 +2,000	+7%	+$3.93K	0.02%	250
2021 Q4	$81K	Buy	30,000 +3,000	+11%	+$11.1K	0.03%	244
2021 Q3	$120K	Sell	27,000 -3,000	-10%	-$14.4K	0.04%	232
2021 Q2	$174K	Buy	30,000 +10,000	+50%	+$58.6K	0.06%	239
2021 Q1	$140K	Buy	20,000 +8,000	+67%	+$53.6K	0.05%	226
2020 Q4	$57K	Buy	12,000 +2,000	+20%	+$10.1K	0.02%	231
2020 Q3	$58K	Buy	+10,000	New	+$59.8K	0.03%	197

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

WealthTrust Axiom's CLVS Position: Q4 2022 in Review

WealthTrust Axiom sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 60,000 shares — an estimated $71K sold.

WealthTrust Axiom first reported a position in CLVS in Q3 2020 and held it in 9 quarters. The position peaked at $174K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

WealthTrust Axiom reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
WealthTrust Axiom sold 60,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $71K.
WealthTrust Axiom first reported a position in Clovis Oncology, Inc. in Q3 2020 and held it in 9 quarters.
WealthTrust Axiom's Clovis Oncology, Inc. position peaked at $174K in Q2 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on WealthTrust Axiom's 13F filing for Q4 2022, filed 31 Jan 2023.